ISO 14064-2:2019 Internal Auditor Free Practice Test — 30 Questions

Question 1

MediCore Solutions, a well-established manufacturer of Class II medical devices, is expanding its product line to include advanced Class III implantable devices. Recognizing the increased regulatory scrutiny and complexity associated with Class III devices, the CEO, Anya Sharma, tasks the Quality Manager, Ben Carter, with integrating the new product line into their existing ISO 13485:2016 certified Quality Management System (QMS). Ben is concerned about maintaining compliance, managing increased risks, and ensuring the QMS effectively supports the new product line without disrupting existing operations. He also needs to ensure that the current QMS documentation and training programs are sufficient for the new devices. Which of the following actions represents the MOST comprehensive and effective approach for Ben to ensure a successful integration of the new Class III product line into MediCore Solutions\' existing ISO 13485:2016 QMS?

Accepted Answer

Conduct a thorough review and update of the QMS documentation, processes, and training programs, including updating the Quality Manual, revising procedures and work instructions, conducting a comprehensive risk assessment for the new product line integrated into the QMS, addressing specific regulatory requirements, establishing communication channels with regulatory bodies, and implementing a robust internal audit program to verify compliance.

Question 2

A multinational medical device manufacturer, "MediCorp Global," is grappling with the complexities of managing separate quality (ISO 13485:2016), environmental (ISO 14001), and occupational health and safety (ISO 45001) management systems across its various global facilities. Each system operates independently, leading to duplicated efforts, inconsistent documentation, and increased administrative overhead. Senior management at MediCorp Global recognizes the need to streamline operations and improve overall efficiency. They are considering integrating these separate management systems into a single, unified framework.

Considering the specific requirements and best practices for integrating ISO 13485:2016 with other management system standards, which of the following approaches would be MOST effective for MediCorp Global to achieve a truly harmonized and efficient integrated management system, ensuring compliance and reducing redundancies across its global operations, while also fostering a culture of continuous improvement and cross-functional collaboration?

Accepted Answer

Conduct a comprehensive gap analysis across all three standards (ISO 13485, ISO 14001, and ISO 45001), develop a unified risk management process integrating ISO 14971 principles, implement integrated audits covering all standards, and secure strong commitment from top management to drive the integration effort.

Question 3

MediCorp Solutions, a medical device manufacturer specializing in Class II devices, is facing increasing challenges in consistently meeting customer requirements and regulatory expectations, resulting in a rise in nonconformities and customer complaints. An internal audit reveals inconsistencies in design outputs and a lack of robust validation processes as primary contributing factors. The company\'s management team is seeking the most effective improvement strategy to address these specific issues within the framework of ISO 13485:2016. Considering the need to enhance product quality, ensure regulatory compliance, and reduce customer dissatisfaction, which of the following strategies would be the MOST impactful and directly address the identified root causes, ensuring a sustainable improvement in the QMS performance related to design and development? The company is particularly concerned about adhering to both FDA regulations and the EU MDR.

Accepted Answer

Implement a comprehensive overhaul of the design and development process, focusing on enhanced design inputs, outputs, verification, validation, and change control procedures, ensuring alignment with both FDA regulations and the EU MDR requirements for design control.

Question 4

\"MedTech Solutions,\" a well-established manufacturer of surgical instruments certified to ISO 13485:2016, is planning a significant expansion. They intend to introduce a new line of implantable medical devices targeted at a different demographic and requiring adherence to stricter regulatory standards in the European Union (EU) under the Medical Device Regulation (MDR). The company\'s current QMS primarily focuses on the existing surgical instrument product line and the associated regulatory requirements in North America. Elara, the newly appointed QMS Manager, is tasked with ensuring the QMS is adequately updated to support this expansion. Considering the requirements of ISO 13485:2016 related to the context of the organization and interested parties, what is the MOST critical initial step Elara should take to ensure the QMS remains effective and compliant after the introduction of the new product line and expansion into the EU market?

Accepted Answer

Conduct a comprehensive reassessment of all interested parties (including customers, regulatory bodies like the EU MDR authorities, suppliers, and employees) and their needs and expectations related to the new product line and the EU market, documenting the findings and using them to update the QMS scope, objectives, and processes.

Question 5

MediCore Devices, a manufacturer of cardiovascular implants, has received a warning letter from a regulatory body (e.g., FDA, EMA) citing deficiencies in its post-market surveillance system. Specifically, the regulatory body alleges that MediCore Devices has not been consistently reporting adverse events and product malfunctions in a timely and accurate manner, as required by applicable regulations. Internal investigations reveal that the company\'s communication with regulatory bodies is ad-hoc and lacks a documented process for ensuring timely and accurate reporting of post-market surveillance data. Considering the requirements of ISO 13485:2016 and the need to maintain effective communication with regulatory authorities, what is the MOST critical action MediCore Devices should take to address the identified deficiencies and prevent future regulatory issues?

Accepted Answer

Establish a formal communication protocol with regulatory bodies, including designated points of contact, defined timelines for reporting, and a clear process for addressing inquiries and providing requested information.

Question 6

MediCore Innovations, a manufacturer of Class IIb medical devices under ISO 13485:2016, is facing challenges in effectively integrating post-market surveillance data into their risk management processes, as mandated by the EU MDR and guided by ISO 14971. Their current system collects data on customer complaints, adverse events, and field safety corrective actions (FSCAs), but struggles to translate this information into proactive risk mitigation strategies. Despite identifying recurring issues related to a specific component failure through post-market data, the risk management file for the device has not been updated to reflect this new information, leading to a potential increase in patient risk. Internal audits have highlighted this deficiency, noting that the risk assessment remains based solely on pre-market data and assumptions.

Considering the requirements of ISO 13485:2016 and its relationship with ISO 14971 regarding risk management and post-market surveillance, which of the following actions is MOST critical for MediCore Innovations to undertake to address this gap and ensure compliance with regulatory requirements?

Accepted Answer

Establish a documented procedure for the systematic review and update of the risk management file based on post-market surveillance data, including defined triggers for re-evaluation, clear responsibilities, and documented evidence of the review process, ensuring alignment with ISO 14971 principles and regulatory expectations.

Question 7

MediTech Innovations is developing a new class III implantable medical device. They are currently in the operational planning phase and need to determine the requirements for their product, as per ISO 13485:2016. This device will be subject to stringent regulatory scrutiny and must meet specific performance criteria to ensure patient safety and efficacy. Considering the requirements of ISO 13485:2016 for operational planning, which of the following approaches would be MOST effective in determining the requirements for this new medical device?

Accepted Answer

Conduct a comprehensive review of applicable regulatory standards, gather customer feedback through surveys and interviews, analyze market data to understand competitive offerings, and define internal requirements based on the company's quality policy and risk management plan.

Question 8

MediCorp, a manufacturer of Class III implantable medical devices, outsources the production of a critical component, a bio-compatible polymer, to ChemTech Solutions. ChemTech has been a long-term supplier, but recent performance data indicates increasing variability in polymer consistency, leading to minor deviations in MediCorp\'s final product testing. Internal investigations suggest that ChemTech\'s raw material sourcing has changed without prior notification to MediCorp, potentially impacting the polymer\'s bio-compatibility. According to ISO 13485:2016 requirements for control of externally provided processes, products, and services, what is MediCorp\'s MOST appropriate immediate course of action to ensure continued compliance and product safety?

Accepted Answer

Conduct a comprehensive re-evaluation of ChemTech, focusing on their updated raw material sourcing, quality management system adherence, and ability to consistently meet MediCorp's specifications and regulatory requirements, documenting all findings and corrective actions taken.

Question 9

MedTech Solutions, a manufacturer of Class II medical devices, recently discovered a recurring issue: inconsistent labeling on their sterile packaging, leading to potential confusion in hospital settings. Investigations revealed that the automated labeling machine occasionally misprints expiration dates due to a faulty sensor. This nonconformity poses a significant risk to patient safety and regulatory compliance under ISO 13485:2016. Considering the requirements of the standard, which of the following actions represents the MOST comprehensive and effective approach to addressing this nonconformity, ensuring both immediate resolution and long-term prevention, while adhering to the documented information requirements? The corrective action process must be clearly documented and demonstrate a commitment to patient safety and regulatory compliance.

Accepted Answer

Replace the faulty sensor on the labeling machine, update the machine's maintenance schedule, retrain the operators on the new maintenance procedures, document the sensor replacement and retraining in the machine's maintenance log, conduct a verification run to confirm the issue is resolved, and update the risk assessment for the labeling process to include sensor failure as a potential hazard.

Question 10

MedTech Solutions, a manufacturer of Class II medical devices, is preparing for its ISO 13485:2016 certification audit. As part of their preparation, they are reviewing their procedures for managing externally provided processes, products, and services. Their current system includes initial evaluation of suppliers based on cost and delivery time, but lacks a formal process for ongoing monitoring of supplier performance beyond occasional checks of incoming goods. Furthermore, they outsource sterilization of their devices to a third-party provider without a documented agreement outlining specific quality requirements or performance metrics. During an internal audit, a significant nonconformity is identified regarding the control of these externally provided elements. To address this nonconformity and ensure compliance with ISO 13485:2016, which of the following actions should MedTech Solutions prioritize to demonstrate a robust and compliant approach to managing externally provided processes, products, and services?

Accepted Answer

Implement a comprehensive system for supplier evaluation based on quality management system, compliance history, and delivery performance; establish a documented agreement with the sterilization provider outlining quality requirements and performance metrics; and implement ongoing monitoring of supplier performance through audits, inspections, and performance reviews.

Question 11

MedTech Solutions, a manufacturer of Class II medical devices, is implementing ISO 13485:2016. They outsource the sterilization of their devices to SterilizeAll Inc. and the manufacturing of a non-critical plastic component to Plastics R Us. Considering the requirements of ISO 13485:2016 regarding the control of externally provided processes, products, and services, what is the MOST appropriate approach for MedTech Solutions to take in evaluating and monitoring these suppliers to ensure compliance with the standard and the quality of their medical devices? The company\'s Quality Manager, Anya Sharma, needs to define the evaluation and monitoring strategy.

Accepted Answer

Conduct a comprehensive on-site audit of SterilizeAll Inc. and a detailed documentation review, followed by ongoing monitoring of their sterilization process, while performing a less rigorous evaluation of Plastics R Us, focusing on certificate of analysis and periodic performance reviews, documenting all activities.

Question 12

MediCore, a manufacturer of orthopedic implants, is undergoing an internal audit as part of its ISO 13485:2016 Quality Management System (QMS). During the audit, it is discovered that the manufacturing process for a specific type of knee implant involves critical process parameters (e.g., temperature, pressure, dwell time) that are not being consistently monitored and documented as required by the established manufacturing procedures. The audit team lead, Kenji, needs to determine the appropriate classification and response to this finding. According to ISO 13485:2016, what is the MOST appropriate action for Kenji to take regarding this finding?

Accepted Answer

Report the finding as a nonconformity, as it indicates a failure to adhere to documented procedures for monitoring and measurement of critical process parameters.

Question 13

MedTech Solutions, a manufacturer of implantable cardiac pacemakers certified to ISO 13485:2016, has established a robust post-market surveillance system as mandated by the EU Medical Device Regulation (MDR). Over the past year, the post-market surveillance team, led by Dr. Anya Sharma, has collected significant data indicating a higher-than-expected rate of premature battery depletion in a specific model of their pacemaker, particularly in patients with high activity levels. This data includes patient feedback, explant analysis, and reports from clinical centers across Europe. The initial risk assessment conducted during the design phase did not adequately anticipate the impact of high activity levels on battery life. Considering the requirements of ISO 13485:2016, particularly concerning risk management (ISO 14971) and regulatory compliance, what is the MOST appropriate course of action for Dr. Sharma and her team?

Accepted Answer

Integrate the post-market surveillance data into the existing risk management file, update the risk assessment to reflect the new information on battery depletion rates under high activity conditions, and initiate corrective actions as necessary, following the nonconformity and corrective action process outlined in ISO 13485:2016.

Question 14

MediCorp Solutions, a medical device manufacturer producing Class II devices for both the US and European markets, is facing increasing challenges in maintaining compliance with ISO 13485:2016. During a recent internal audit, several nonconformities were identified, including inconsistencies between the company\'s documented procedures and actual practices, particularly concerning design validation and post-market surveillance. The FDA has recently issued updated guidance on design controls, while the EU MDR has introduced more stringent requirements for post-market clinical follow-up (PMCF). Different departments within MediCorp interpret these changes differently, leading to conflicting documentation and operational practices. The CEO, Alisha Kapoor, is concerned that these discrepancies could lead to regulatory action and market access issues. The Quality Manager, Javier Rodriguez, is tasked with addressing these compliance gaps. Javier reviews the audit findings and identifies several potential corrective actions. Considering the requirements of ISO 13485:2016 and the need to comply with both FDA and EU MDR regulations, what is the MOST effective approach for Javier to recommend to Alisha to ensure MediCorp\'s continued compliance and mitigate the identified risks?

Accepted Answer

Establish a comprehensive and integrated documented information system that addresses both FDA and EU MDR requirements, incorporating risk-based thinking and a mechanism for regularly updating the system to reflect changes in regulations.

Question 15

\"MediCore Solutions,\" a manufacturer of Class II medical devices, is undergoing an internal audit of its Quality Management System (QMS) according to ISO 13485:2016. The internal auditor, Anya Sharma, is reviewing the company\'s documented procedures for post-market surveillance, specifically focusing on the handling of customer complaints and adverse event reporting. During her review, Anya notices that the documented procedure states that all customer complaints are to be investigated within 60 days of receipt, and adverse events are to be reported to the relevant regulatory authority within 90 days of the initial complaint. However, Anya is aware that the EU Medical Device Regulation (MDR) mandates that serious adverse events must be reported to the competent authority within a maximum of 30 days of awareness. Considering ISO 13485:2016 requirements for documented information and regulatory compliance, what should Anya identify as the MOST significant non-conformity during her audit?

Accepted Answer

The documented procedure for adverse event reporting does not align with the EU MDR's stipulated reporting timelines for serious adverse events, potentially leading to regulatory non-compliance.

Question 16

MediCore Solutions, a manufacturer of implantable cardiac pacemakers, is implementing ISO 13485:2016. During the initial planning phase, the management team is debating the scope of their Quality Management System (QMS). Alistair, the VP of Operations, argues that the QMS should primarily focus on the design and manufacturing processes within their facility to streamline implementation and reduce initial costs. Dr. Anya Sharma, the Chief Medical Officer, insists that the QMS must also include post-market surveillance activities and the handling of adverse event reports. Considering that MediCore provides installation and servicing of their pacemakers directly to hospitals and also manages the final decommissioning of explanted devices due to regulatory requirements concerning hazardous materials, what would be the most appropriate scope definition for MediCore\'s QMS under ISO 13485:2016 to ensure compliance and effectiveness?

Accepted Answer

The QMS scope should encompass the design, manufacturing, installation, servicing, and decommissioning of pacemakers, including post-market surveillance and adverse event reporting, while considering all applicable regulatory requirements such as FDA regulations and EU MDR.

Question 17

MediTech Solutions, a manufacturer of Class III implantable medical devices, outsources the sterilization process to SterilePro, a third-party vendor. During an internal audit against ISO 13485:2016, the auditor discovers that MediTech has not established clear, documented requirements for the sterilization process performed by SterilePro. There is no formal quality agreement outlining acceptance criteria, monitoring activities, or verification methods. Furthermore, MediTech does not conduct regular audits of SterilePro to verify compliance with regulatory requirements and MediTech\'s quality standards. Considering the requirements of ISO 13485:2016 regarding the control of externally provided processes, products, and services, what is the most appropriate recommendation for the internal auditor to make to MediTech Solutions to address this gap and ensure compliance with the standard, while also mitigating potential risks associated with the outsourced sterilization process, especially given the critical nature of Class III devices and the stringent regulatory oversight they are subject to?

Accepted Answer

Recommend that MediTech Solutions establish clear, documented requirements for the sterilization process, including acceptance criteria, monitoring activities, and verification methods, formalized in a quality agreement; conduct regular audits of SterilePro to ensure compliance; and implement a robust process for addressing nonconformities and implementing corrective actions.

Question 18

Stellaris Medical, a manufacturer of implantable cardiac devices, is facing significant challenges with their current supplier of biocompatible polymers, a critical component in their devices. Over the past six months, the supplier has exhibited inconsistent material properties, leading to deviations in the final product\'s performance. Additionally, there have been repeated instances of delayed deliveries, threatening Stellaris\'s ability to meet production schedules and fulfill customer orders. Internal audits have identified that the supplier\'s quality management system (QMS) appears to be deteriorating, with evidence of inadequate process controls and insufficient corrective actions. Stellaris Medical operates under a strict ISO 13485:2016 certified QMS and is subject to stringent regulatory oversight by the FDA. Given these circumstances and considering the requirements of ISO 13485:2016 regarding the control of externally provided processes, products, and services, what is the MOST appropriate course of action for Stellaris Medical to take to ensure continued compliance and product quality, minimizing potential risks to patient safety and regulatory repercussions?

Accepted Answer

Conduct a comprehensive re-evaluation of the existing supplier's QMS, performance, and adherence to regulatory requirements, and if deficiencies are significant and unresolvable, transition to a qualified alternative supplier, documenting the entire process.

Question 19

MediCore Innovations, a manufacturer of implantable cardiac pacemakers, is undergoing its initial ISO 13485:2016 implementation. An internal audit reveals several nonconformities related to the design and development process, specifically inadequate design verification and validation documentation for a new pacemaker model. The audit team finds that design inputs were not adequately translated into design outputs, and validation activities did not fully simulate real-world usage conditions. Considering the requirements of ISO 13485:2016, what is the MOST appropriate and comprehensive course of action for MediCore Innovations to address these nonconformities and ensure ongoing compliance? Assume the company is already aware of the need for documentation.

Accepted Answer

Conduct a root cause analysis to identify the underlying reasons for the inadequate design verification and validation, implement corrective actions to prevent recurrence, verify the effectiveness of the corrective actions, and document the entire process as part of the QMS.

Question 20

MedTech Solutions, a multinational medical device manufacturer, is undergoing an internal audit of its Quality Management System (QMS) certified to ISO 13485:2016. The audit team, led by senior auditor Ingrid, is focusing on the integration of risk management principles across various processes. During the audit, the team observes that while the design and development phase incorporates comprehensive risk assessments aligned with ISO 14971, the post-market surveillance activities appear less structured, relying primarily on customer complaints rather than proactive risk monitoring. Furthermore, the team notes that the documented procedures for handling field safety corrective actions (FSCAs) lack clear linkages to the initial risk assessments conducted during product design. Considering the requirements of ISO 13485:2016 and its emphasis on a lifecycle approach to risk management, what is the most critical area for improvement that Ingrid should highlight in her audit report to ensure compliance and enhance patient safety?

Accepted Answer

Strengthening the integration of risk management principles into post-market surveillance activities, ensuring proactive risk monitoring, and establishing clear linkages between FSCAs and initial risk assessments conducted during product design, aligning with ISO 14971 and relevant regulatory requirements like the EU MDR.

Question 21

MedTech Solutions, a manufacturer of Class III implantable medical devices, sources a critical component from an external supplier, \"Precision Components Inc.\" Recent internal audits have revealed a significant increase in non-conforming components received from Precision Components Inc., leading to production delays and potential risks to product safety. The audit findings indicate inconsistencies in material certifications, dimensional inaccuracies, and inadequate process controls at the supplier\'s facility. These issues directly impact the final product\'s functionality and compliance with stringent regulatory requirements under both FDA and EU MDR guidelines. MedTech Solutions\' Quality Manager, Alem Tesfaye, is tasked with addressing this supplier performance issue according to ISO 13485:2016 requirements. Considering the criticality of the component and the supplier\'s recent performance, which of the following actions should Alem prioritize as the MOST comprehensive and immediate step to ensure compliance and mitigate risks?

Accepted Answer

Conduct a comprehensive re-evaluation of Precision Components Inc.'s quality management system, focusing on design controls, manufacturing processes, testing protocols, and regulatory compliance, performed by a qualified team, with documented findings and corrective action plans.

Question 22

MedTech Solutions, a manufacturer of Class II medical devices, has recently undergone its annual post-market surveillance review as mandated by ISO 13485:2016. The review highlighted a recurring issue reported by users: a higher-than-expected failure rate of a specific component in their infusion pumps, leading to potential dosage inaccuracies. The post-market surveillance data clearly indicates a potential safety risk that was not adequately addressed during the initial design and development phase. According to ISO 13485:2016 requirements regarding risk management and operational planning, what is the MOST appropriate immediate action for the Quality Manager, Anya Sharma, to take to address this newly identified risk and ensure ongoing compliance with the standard? Anya must prioritize actions that directly impact product safety and regulatory adherence.

Accepted Answer

Modify the operational planning documents to incorporate the findings from the post-market surveillance data, updating risk assessments and mitigation strategies for the infusion pump component.

Question 23

MediCore Innovations, a manufacturer of advanced surgical instruments, is preparing for its initial ISO 13485:2016 certification audit. The company\'s management team, led by CEO Anya Sharma, is keen to establish a robust Quality Management System (QMS). During the initial planning phase, Anya emphasizes the importance of understanding the \'context of the organization\' as stipulated in the standard. She tasks the QMS implementation team, headed by quality manager Kenji Tanaka, with identifying and analyzing relevant factors. Kenji\'s team identifies hospitals, surgeons, regulatory bodies (such as the FDA and EU MDR authorities), suppliers of raw materials, and distributors as key stakeholders.

Given this scenario and considering the requirements of ISO 13485:2016, which of the following actions is MOST crucial for MediCore Innovations to effectively address the \'context of the organization\' and ensure a compliant and effective QMS?

Accepted Answer

Thoroughly identifying all interested parties relevant to the QMS, determining their requirements that are relevant to the QMS, and defining the scope of the QMS based on this understanding.

Question 24

MediCorp Solutions, a manufacturer of Class II medical devices, is currently certified to ISO 9001:2015. However, with increasing regulatory scrutiny and the upcoming transition to the EU Medical Device Regulation (MDR), they recognize the need to upgrade their Quality Management System (QMS) to comply with ISO 13485:2016. Their current QMS struggles with consistent product quality, particularly in design control, supplier management, and post-market surveillance. The executive leadership team, led by CEO Anya Sharma, is committed to achieving ISO 13485 certification. Given their existing ISO 9001 certification and the identified weaknesses in their current QMS, what is the most effective initial step MediCorp should take to align with ISO 13485:2016 and prepare for the EU MDR requirements, considering the need for a structured and efficient approach?

Accepted Answer

Conduct a comprehensive gap analysis of their existing ISO 9001:2015 QMS against the requirements of ISO 13485:2016, including specific consideration of EU MDR requirements, to identify areas needing improvement in design control, supplier management, and post-market surveillance.

Question 25

BioSecure Devices, a manufacturer of in-vitro diagnostic devices, is implementing ISO 13485:2016. During the initial documentation phase, a debate arises between the engineering and quality assurance departments regarding the level of detail required in work instructions for the assembly of a new diagnostic kit. The engineering team argues for concise instructions to allow flexibility and innovation, while the quality assurance team insists on highly detailed instructions to ensure consistency and minimize the risk of errors. Considering the requirements of ISO 13485:2016, what approach should BioSecure Devices adopt to determine the appropriate level of detail for the work instructions?

Accepted Answer

Conduct a risk assessment to identify potential risks associated with the assembly process and determine the level of detail in the work instructions based on the severity and likelihood of those risks, ensuring that critical steps are clearly defined and controlled.

Question 26

MediCorp Innovations, a medical device manufacturer certified to ISO 13485:2016, is experiencing persistent issues with components supplied by Precision Components. These components consistently fail to meet specifications, leading to production delays and increased costs. As an internal auditor tasked with investigating this issue, you\'ve identified that the problem seems to stem from inadequate supplier quality management. According to ISO 13485:2016 requirements regarding the control of externally provided processes, products, and services, which of the following initial actions would be most appropriate for you to take as the internal auditor to address this situation effectively and ensure compliance? Your investigation should take into consideration the need to comply with regulatory requirements such as those from the FDA and EU MDR related to supplier control. The goal is to identify the root cause of the supplier performance issues and implement corrective actions to prevent future occurrences, while maintaining the integrity of MediCorp\'s QMS. The audit should also ensure that MediCorp is fulfilling its obligations to monitor and re-evaluate its suppliers according to a defined schedule and criteria.

Accepted Answer

Review MediCorp's documented procedures for supplier evaluation and selection to ensure they meet ISO 13485:2016 requirements and are properly implemented.

Question 27

MediCorp, a rapidly growing medical device manufacturer specializing in Class II devices, is facing increasing pressure from its investors to expedite the launch of its new line of advanced wound care products. The CEO, Alisha, is concerned that the company\'s ISO 13485:2016 implementation, while progressing, is slowing down the product development cycle. Alisha proposes to temporarily relax certain design verification and validation protocols and reduce the frequency of supplier audits to accelerate the launch. The Quality Manager, Ben, strongly opposes this, arguing that it would compromise the integrity of the QMS and potentially violate regulatory requirements. The investors are pushing for immediate results, threatening to withdraw funding if the product launch is not significantly accelerated. Considering the requirements of ISO 13485:2016, the potential regulatory implications (including FDA regulations), and the long-term sustainability of MediCorp, what is the most appropriate course of action for Alisha and her management team?

Accepted Answer

Develop a balanced strategy that optimizes processes, leverages technology to improve efficiency, and prioritizes resources to focus on critical areas without compromising the integrity of the QMS, while also communicating transparently with investors about the importance of quality and compliance for long-term success.

Question 28

MedTech Innovations, a company specializing in surgical robotics, is preparing for its annual ISO 13485:2016 management review. Dr. Ramirez, the CEO, wants to ensure the review is comprehensive and addresses all key aspects of the quality management system. He has tasked his team with gathering the necessary inputs. Given the requirements of ISO 13485:2016, which of the following represents the most complete and critical set of inputs that MedTech Innovations must consider during its management review to ensure the QMS remains effective, suitable, and adequate for its intended purpose and regulatory compliance?

Accepted Answer

Customer feedback data, internal audit results, process performance data, the status of corrective actions, and recommendations for improvement, along with an assessment of resource needs to maintain the QMS.

Question 29

\"OrthoImplants,\" a company that designs, manufactures, and distributes orthopedic implants, is facing increasing pressure from regulatory bodies to demonstrate compliance with stricter post-market surveillance requirements. The company\'s current post-market surveillance system primarily relies on passive data collection from customer complaints and adverse event reports. However, the regulatory authorities are now requiring more proactive and comprehensive data collection and analysis to identify potential safety issues and trends. Considering the requirements of ISO 13485:2016 and the evolving regulatory landscape, what specific actions should OrthoImplants take to enhance its post-market surveillance system and ensure ongoing compliance?

Accepted Answer

Implement a proactive post-market surveillance system that includes systematic data collection from multiple sources, such as clinical studies, patient registries, and social media, and utilize data mining and statistical analysis techniques to identify potential safety signals and trends.

Question 30

BioTech Solutions, a company specializing in implantable medical devices, is undergoing an internal audit for ISO 13485:2016 certification. During the audit, the internal auditor, Anya Sharma, discovers that while the company has a documented procedure for handling customer complaints and adverse events post-market, there\'s a lack of documented evidence demonstrating a proactive, systematic approach to identifying potential hazards and associated risks during the design and development phase. The design team primarily relies on the engineers\' experience and informal discussions to address potential risks. Furthermore, there\'s no clear link between the post-market surveillance data and the initial risk assessments conducted during design. According to ISO 13485:2016, what is the MOST significant area of non-compliance Anya should highlight in her audit report regarding risk management?

Accepted Answer

The absence of a formally documented risk management process, aligned with ISO 14971, that is integrated throughout the QMS and covers all stages of the medical device lifecycle, including hazard identification, risk analysis, risk evaluation, risk control, and post-market surveillance feedback.

ISO 14064-2:2019 Internal Auditor Free Practice Test — 30 Questions

A lot more is already mapped out

About the ISO 14064-2:2019 Internal Auditor Certification